Related Experiment Video
Updated: Aug 24, 2025
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
Study of KRAS-Related miRNA Expression in Colorectal Cancer
Xiaobing Wu1, Zhifa Li1, Nanqi Huang1
1Gastrointestinal Surgery, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, People's Republic of China.
Introduction:
Colorectal cancer (CRC) is one of the most common digestive system tumors and seriously threatens the lives of patients. The choice of treatment options and the prognosis of CRC patients are closely related to the KRAS genotype. Notably, microRNAs (miRNAs) have great application value in the diagnosis and treatment of CRC.
Methods:
The current study used qRT-PCR to analyze the expression of KRAS-targeting miRNAs and determine the correlation between miRNA expression and KRAS gene expression among patients with varying genotypes. The effect of the KRAS gene on the prognosis of patients with cancer was determined.
Results:
Eighty-two differentially expressed miRNAs were identified between CRC tumor and normal tissues: 58 dysregulated miRNAs were identified in patients with KRAS mutations, and 62 aberrantly expressed miRNAs were detected in patients with wild-type KRAS. Thirteen miRNAs were abnormally expressed in KRAS-mutant patients compared with KRAS wild-type patients. Some miRNAs not only acted as biomarkers for CRC but also indicated the genotype of KRAS.
Conclusion:
This finding is very important for patients who must choose from clinical treatment options based on KRAS results. Thus, the abnormal expression of miRNAs has great application potential for the selection of chemotherapy regimens for patients with cancer. The relationship between differential miRNA expression and the KRAS genotype is very important for studying related mechanisms in CRC.
Insights
MicroRNAs (miRNAs) can serve as biomarkers for colorectal cancer (CRC) and indicate KRAS genotype. This finding aids in selecting chemotherapy regimens for CRC patients based on their KRAS status.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Colorectal cancer (CRC) poses a significant health threat, with patient prognosis and treatment choices linked to KRAS genotype.
- MicroRNAs (miRNAs) show promise in CRC diagnosis and treatment.
- Understanding the interplay between miRNAs and KRAS genotype is crucial for personalized medicine.
Purpose of the Study:
- To investigate the expression patterns of KRAS-targeting miRNAs in CRC.
- To determine the correlation between miRNA expression and KRAS gene status in CRC patients.
- To explore the potential of miRNAs as biomarkers for CRC and KRAS genotype prediction.
Main Methods:
- Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was employed to analyze miRNA expression.
- Expression levels of KRAS-targeting miRNAs were correlated with KRAS gene expression.
- Differential miRNA expression was compared between CRC tumor and normal tissues, and between KRAS-mutant and wild-type KRAS patients.
Main Results:
- Eighty-two differentially expressed miRNAs were identified in CRC tissues compared to normal tissues.
- 58 miRNAs were dysregulated in patients with KRAS mutations, and 62 in those with wild-type KRAS.
- Thirteen miRNAs showed differential expression between KRAS-mutant and wild-type KRAS patients, suggesting their potential as genotype indicators.
Conclusions:
- Abnormal miRNA expression is linked to CRC and can indicate KRAS genotype.
- miRNAs hold significant potential as biomarkers for CRC diagnosis and for guiding chemotherapy regimen selection.
- Further research into miRNA-KRAS genotype relationships can elucidate CRC mechanisms and improve patient outcomes.
Related Concept Videos
01:22MicroRNAs
02:38The Ras Gene
Ras is a...